Product Description
Mechanisms of Action: CYSLT1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Colombia | Dominican Republic | Japan | Korea | Peru | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Jichuan Pharmaceutical Group Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Sinusitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20231693 |
CTR20231693 | N/A |
Completed |
Asthma, Allergic|Rhinitis, Allergic |
2023-10-08 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Trial Status |
|
NCT00410735 |
ONO-1078-37 | P3 |
Completed |
Sinusitis |
2008-06-01 |
2019-03-21 |
Treatments |